Volume 60, Issue 10 pp. 2225-2242
TRANSFUSION PRACTICE

Red blood cell and platelet transfusion support in the first 30 and 100 days after allogeneic hematopoietic cell transplant

Shan Yuan

Corresponding Author

Shan Yuan

Division of Transfusion Medicine, Department of Pathology, City of Hope National Medical Center, Duarte, California, USA

Correspondence

Shan Yuan, Division of Transfusion Medicine, Department of Pathology, City of Hope National Medical Center, Duarte, CA 91010-3000.

e-mail: [email protected]

Search for more papers by this author
Dongyun Yang

Dongyun Yang

Division of Biostatistics, Department of Computational and Quantitative Medicine, City of Hope National Medical Center, Duarte, California, USA

Search for more papers by this author
Ryotaro Nakamura

Ryotaro Nakamura

Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA

Search for more papers by this author
Lefan Zhuang

Lefan Zhuang

Division of Transfusion Medicine, Department of Pathology, City of Hope National Medical Center, Duarte, California, USA

Search for more papers by this author
Monzr M. Al Malki

Monzr M. Al Malki

Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA

Search for more papers by this author
Chatchada Karanes

Chatchada Karanes

Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA

Search for more papers by this author
Shirong Wang

Shirong Wang

Division of Transfusion Medicine, Department of Pathology, City of Hope National Medical Center, Duarte, California, USA

Search for more papers by this author
First published: 03 August 2020
Citations: 12

Abstract

Background

Allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients often require substantial but variable transfusion support.

Study Design and Methods

This single-center, retrospective study evaluated the red blood cell (RBC) and platelet (PLT) transfusion data of first-time allo-HSCT recipients transplanted in 2011 to 2017. Multivariate analyses were performed to assess the associations between patient and transplant-related factors and transfusion requirements.

Results

The study included 1762 patients who received peripheral blood stem cells (88.2%), marrow (7.0%), or umbilical cord (4.8%) from matched related (38.3%), unrelated (49.2%), or haploidentical (7.8%) donors. Almost all patients required RBCs (88.3%) or PLTs (97.4%) during the first 30 days, with medians of 3 (range, 1-37) RBC and 6 (range, 1-144) PLT units transfused. Fewer patients required RBC (43.8%) or PLT (27.3%) transfusions during Days 31 to 100, but the median (range) numbers of RBC and PLT units remained high at 3 (1-36) and 6 (1-116) among transfused patients. RBC and PLT transfusion independence was reached in medians of 24 (95% confidence interval [CI], 22-26) and 12 (95% CI, 11-12) days, respectively. Haploidentical donor, cord graft, and requiring RBC transfusions in the 10 days before HSCT were the most significant independent factors predictive of increased transfusion requirements. Advanced disease, diagnosis, ABO incompatibility, conditioning intensity, CD34+ cell dose, presence of severe acute graft-vs-host disease, and changes in recommended transfusion triggers were also shown to independently impact transfusion requirements.

Conclusions

This study provided for the first time quantitative and comparative transfusion data on a large contemporary cohort of HSCT recipients, including haploidentical and cord graft recipients, and identified factors predictive of increased transfusions.

CONFLICT OF INTEREST

The authors declare no potential conflict of interest.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.